Pages that link to "Q50504945"
Jump to navigation
Jump to search
The following pages link to Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin (Q50504945):
Displaying 5 items.
- Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma. (Q52570980) (← links)
- Targeting Cancer Stem Cells to Overcome Chemoresistance (Q60956875) (← links)
- Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer (Q90422482) (← links)
- Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies (Q93000421) (← links)
- Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer (Q96132947) (← links)